BIO JOINS AMICUS BRIEF CHALLENGING COURT’S EFFORTS TO UNDERMINE FDA’S AUTHORITY TO BRING TREATMENTS AND CURES TO PATIENTS

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s authority to approve life-saving and life-enhancing therapies to patients.

The amicus brief, which was filed in the U.S. Court of Appeals for the Fifth Circuit, asks the court to suspend the District Court’s ruling until the appeal can be heard. BIO’s executive committee unanimously agreed to have BIO sign onto this amicus brief.